Quantcast

Latest Endo International plc Stories

2014-09-08 12:29:43

DUBLIN, Sept. 8, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that Rajiv De Silva, President and CEO, will present a corporate overview at the Morgan Stanley Global Healthcare Conference 2014 on Tuesday, September 9, 2014 at 4:05 p.m. Eastern Time. A live webcast and audio archive for the event will be available on the company's website at www.endo.com . Click on Investor Relations, and then the link to the event. Participants should allow...

2014-09-08 08:29:47

First and only generic 2% topical testosterone gel DUBLIN, Sept. 8, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that it has introduced the first and only generic 2% topical testosterone gel, an authorized generic of FORTESTA® Gel (testosterone gel) CIII. FORTESTA Gel and its Authorized Generic version are the first and only 2% testosterone gels approved by the U.S. Food and Drug Administration to treat adult males diagnosed with hypogonadism. The...

2014-08-06 16:30:14

DUBLIN, Aug. 6, 2014 /PRNewswire/ -- -- Adds high-margin marketed generics portfolio, robust near-term ANDA pipeline to Endo's existing generics portfolio -- Ability to leverage Endo's proven commercial expertise to maximize profitable growth -- Company raises expected 2014 revenues to a range from $2.78 billion to $2.86 billion, an increase versus prior range of $2.72 billion to $2.80 billion. -- Company raises expected 2014 adjusted...

2014-07-31 08:34:38

-- Total quarterly revenues of $719 million, reported diluted (GAAP) EPS of $0.13 and adjusted diluted EPS of $1.06. DUBLIN, July 31, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported second quarter 2014 revenues of $719 million, an increase of 1 percent compared to second quarter 2013 revenues of $712 million. Endo reported net income of $21 million in the second quarter 2014 compared to net income of $35 million in the second quarter of 2013. As detailed...

2014-07-30 16:29:49

DUBLIN, July 30, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced the appointment of Shane M. Cooke to the company's board of directors. Mr. Cooke, an international business leader with more than 25 years of experience, currently serves as president of Alkermes plc based in Dublin, Ireland. Mr. Cooke has also been appointed to Endo's Audit and Transactions Committee. "I am excited to welcome Shane to our board of directors," said Roger Kimmel,...

2014-07-24 16:27:46

DUBLIN, July 24, 2014 /PRNewswire/ -- -- Advances Endo's transformation into a leading global specialty healthcare company -- Establishes a platform for growth in key Latin American emerging markets -- Norbert Oppitz appointed Regional President, Latin America, Africa and Export Markets Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that it has completed the acquisition of Grupo Farmaceutico Somar(®) (Somar), a leading, privately owned...

2014-07-15 08:29:31

DUBLIN, July 15, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) will announce its second quarter 2014 financial results before the open of the U.S. financial markets on July 31, 2014 and members of its senior management team will host a conference call and webcast at 8:30 a.m. ET that day. The dial-in number to access the call is U.S./Canada (877) 415-3179, International (857) 244-7322, and the passcode is 75265738. Please dial in 10 minutes prior to the...

2014-07-07 08:27:32

- Pre-NDA meeting scheduled with FDA in July DUBLIN and RALEIGH, N.C., July 7, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require...

2014-06-26 00:21:04

DUBLIN, June 25, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo") today announced that Endo Finance LLC and Endo Finco Inc., its wholly-owned subsidiaries, priced $750 million aggregate principal amount of 5.375% senior notes due January 2023 at an issue price of $1,000 per $1,000 principal amount in connection with their previously announced private offering. The notes will be unsecured, unsubordinated obligations of Endo Finance LLC and Endo Finco Inc....

2014-06-25 08:30:12

DUBLIN, June 25, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) ("Endo") today announced that Endo Finance LLC and Endo Finco Inc., its wholly-owned subsidiaries, intend to offer senior notes, subject to market and customary conditions. The notes will be unsecured, unsubordinated obligations of Endo Finance LLC and Endo Finco Inc. and will be guaranteed by Endo Limited, a wholly-owned subsidiary of Endo, and certain of Endo Limited's direct and indirect...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related